Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Roy Koruth"'
Autor:
Peter Mohr, Felix Kiecker, Virtudes Soriano, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, Florencia Cuadros, Matias Chacón, Rodrigo U Villarroel, Yana G Najjar, Lisa Kottschade, Eva M Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu-Ittu, Maurice Perrinjaquet, Jonathan S Zager
Publikováno v:
Melanoma Management, Vol 6, Iss 4 (2019)
Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Ch
Externí odkaz:
https://doaj.org/article/3793d2a3b1484aed83d8938e4ccc0f12
Autor:
Dinesh Mishra, Margaret E. Gerbasi, Roy Koruth, Sameer R. Ghate, Briana Ndife, Aaron Moynahan, Daniel Stellato, P Gunda, Thomas E. Delea
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:1227-1237
Before the approval of dabrafenib and trametinib in combination, there were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK pathway.To evaluate the budget impact of dabrafenib and trametinib in combination for adjuvant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5112ed55d08cc354d994682606656a84
https://doi.org/10.18553/jmcp.2019.25.11.1227
https://doi.org/10.18553/jmcp.2019.25.11.1227
Autor:
Margaret E. Gerbasi, Briana Ndife, Thomas E. Delea, Aaron Moynahan, Roy Koruth, Daniel Stellato, P Gunda, Dinesh Mishra, Sameer R. Ghate
Publikováno v:
Journal of Medical Economics. 22:1243-1252
Objective The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination versus placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115bb8bd22b0e71a8756ed2a68b53d3a
https://doi.org/10.1080/13696998.2019.1635487
https://doi.org/10.1080/13696998.2019.1635487
Autor:
Vanna Chiarion-Sileni, James Larkin, Richard F. Kefford, John M. Kirkwood, Mario Mandalà, Stephanie Manson, Kohinoor Dasgupta, Victoria Atkinson, Thierry Lesimple, Marta Nyakas, Reinhard Dummer, Axel Hauschild, Andrew Haydon, Laurent Mortier, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Bijoyesh Mookerjee, Mario Santinami, Ruth Plummer, Caroline Dutriaux, Jacob Schachter, Roy Koruth
Publikováno v:
The Lancet Oncology. 20:701-710
Summary Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that dabrafenib plus trametinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53df44a4ff8cc03f79d33dd8da0b9b06
https://doi.org/10.1016/s1470-2045(18)30940-9
https://doi.org/10.1016/s1470-2045(18)30940-9
Publikováno v:
Journal of comparative effectiveness research. 8(16)
Aim To conduct a systematic literature review of high-risk resectable cutaneous melanoma adjuvant therapeutics and compare safety and efficacy. Methods: The systematic literature review included randomized controlled trials investigating: dabrafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f129f5c06109c2061b50c615f621c4b5
https://pubmed.ncbi.nlm.nih.gov/31778073
https://pubmed.ncbi.nlm.nih.gov/31778073
Autor:
Dirk, Schadendorf, Axel, Hauschild, Mario, Santinami, Victoria, Atkinson, Mario, Mandalà, Vanna, Chiarion-Sileni, James, Larkin, Marta, Nyakas, Caroline, Dutriaux, Andrew, Haydon, Caroline, Robert, Laurent, Mortier, Thierry, Lesimple, Ruth, Plummer, Jacob, Schachter, Kohinoor, Dasgupta, Stephanie, Manson, Roy, Koruth, Bijoyesh, Mookerjee, Richard, Kefford, Reinhard, Dummer, John M, Kirkwood, Georgina V, Long
Publikováno v:
The Lancet. Oncology. 20(5)
In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAFCOMBI-AD was a randomised, double-blind, placebo-controlled, phase 3 study done at 169 sites in 25 countries. Study participants were aged 18 years or older and had co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc566fa1638b0763d2651b0f880c24d9
https://pubmed.ncbi.nlm.nih.gov/30928621
https://pubmed.ncbi.nlm.nih.gov/30928621
Autor:
Rodrigo U Villarroel, Rama Koneru, Virtudes Soriano, Jonathan S. Zager, Roy Koruth, Olivier Dereure, Maurice Perrinjaquet, Karmele Mujika, Felix Kiecker, Eva Muñoz Couselo, Lisa A. Kottschade, Yana G. Najjar, Peter Mohr, Raluca Ionescu-Ittu, Matias Chacón, Philippe Saiag, Rebecca Burne, Jochen Utikal, Florencia Cuadros, Caroline Robert, Annie Guerin
Publikováno v:
Melanoma Management
Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5aa68063aa5a868712c65807c52b74
https://doi.org/10.2217/mmt-2019-0015
https://doi.org/10.2217/mmt-2019-0015
Publikováno v:
Protein expression and purification. 9(3)
We have developed a procedure for the quantitative refolding of the Link module from human tumor necrosis factor-stimulated gene 6. This significantly simplifies the previously described method of production of this protein domain (Day et al., Protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93795e648f9d2dfe46e77e88ee524299
https://pubmed.ncbi.nlm.nih.gov/9126602
https://pubmed.ncbi.nlm.nih.gov/9126602